A Clinical Pharmacological Study to Assess the Distribution, Metabolism, and Elimination of YM155 After i.v. Infusion in Patients With Advanced Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2014

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Sepantronium bromide (Primary)
Indications Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Non-small cell lung cancer; Prostate cancer
Focus Pharmacokinetics
Sponsors Astellas Pharma

14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
18 Mar 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
18 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com